Ketamine hydrochloride is a safe and rapid-acting non-opioid, lipid soluble anaesthetic with a short elimination halflife that is used for medical and veterinary purposes. It produces a state of "dissociative anaesthesia", probably from action on N-methyl-D-aspartate (NMDA) receptors. The psychotropic effects of ketamine range from dissociation and depersonalization to psychotic experiences and include a sensation of feeling light, body distortion, absence of time sense, novel experiences of cosmic oneness and out-of-body experiences. Abuse of ketamine has been reported, the typical abuser being an individual who uses multiple drugs and has some contact with medical agencies. This case demonstrates the effects of large doses of ketamine in a person with polysubstance abuse. The case also highlights development of significant tolerance to ketamine without prominent withdrawal symptoms. Caution in use of ketamine is reiterated in light of its abuse liability.
Ketamine hydrochloride is a safe and rapid-acting analgesic and anaesthetic for medical and veterinary use. It is a non-opioid anaesthetic compound with the chemical formula 2-chlorophyl 1-2-methylamino cyclohexanone hydrochloride. It has phencyclidine phosphate (PCP)-like behavioural effects. Ketamine is lipid soluble, with a short elimination half-life (2-3 h) and an early onset of action (depending on the route). The intravenous anaesthetic dose is 1-2 mg/kg body weight. It produces a state of "dissociative anaesthesia" probably via N-methyl-D-aspartate receptors. This is due to selective interruption of associative pathways connecting the thalamo-neocortical and limbic systems 2 as well as from selective inhibition and stimulation respectively of these two systems.
The psychotropic effects of ketamine range from dissociation and depersonalization to psychotic experiences. These have sometimes been reported as pleasant whereas many have found them to be extremely distressing. Common experiences reported include a sensation of feeling light, body distortion, absence of time sense, novel experiences of cosmic oneness, out-of-body experiences and so on 3 . The effects depend on set (state of mind) and the setting (familiar or unfamiliar). These effects are brief, depending on the dose and route, but usually last up to 30 minutes 4 .
There are only case and media reports about illicit use of ketamine. In a series 5 describing 22 cases with illicit use, ketamine abuse occurred in the setting of polydrug abuse. Tolerance develops, with consequent increase in the dose of ketamine abused, and the perceived effects can generally be discriminated from other drugs by users even when this occurs in a polydrug abuse setting. Studies have addressed the issue of perceived and observed effects of ketamine in recreational users and volunteers. In a comparative evaluation of polydrug users who abused ketamine that was designed to discriminate between acute and chronic effects 6 , the dissociative and schizotypal symptoms were found to persist beyond three days. Ketamine administration produces semantic memory deficits that may persist. However a case report 7 of an individual who used 750 mg ketamine five to six times a day described no residual chronic effects.
Ketamine abuse as an illicit drug or a substance for recreational use has not been reported from India. A case of ketamine dependence seen in the deaddiction centre at the All India Institute of Medical Sciences is presented here.
CASE HISTORY
The patient was a 28-year-old unmarried graduate male with a family history of alcohol dependence in his elder brother and cannabis abuse in another male sibling. He presented with complaints of cannabis use for 17 years, alcohol use for 15 years and injection use of pentazocine followed by ketamine for five to six years. The patient started cannabis use at 11 years of age, and had been a dependent user of cannabis for nearly 10 years at the time of presentation. He started using alcohol at 18 years of age and rapidly escalated this to about 750 ml of distilled spirits within four to five months of his onset of drinking daily. Within five years of alcohol abuse, he experienced physiological signs and symptoms of alcohol withdrawal and strong persistent craving after brief abstinence. At the age of about 24 years he changed to the use of injectable drugs, beginning with pentazocine. This was mostly mixed with promethazine or diazepam and administered intramuscularly initially and intravenously subsequently. He also gradually increased the dose over a four-year period to 400 to 500 mg of pentazocine a day in five to six divided doses. In an attempt to give up pentazocine, as well as overcome the withdrawal effects, he contacted a pharmacist friend. The friend injected the patient with ketamine intravenously without the patient's knowledge about the nature of medication. The patient lost consciousness immediately upon injection and had to be carried home. Within a few days he returned to the same friend with complaints of distress from not having taken pentazocine. This time the patient experienced relief from his distress by intravenous ketamine, without losing consciousness. The patient continued to procure ketamine from the friend and injected himself with 2 to 4 ml (100-200 mg) daily. This was injected mostly intramuscularly into the anterior thigh in about three to four sittings at home or at the shop where he was working. The experiences described after each dose of ketamine were similar and mostly pleasant in nature. He described these as altered perception of time, feeling of floating in air, increase in size of his hand and arm, watching his own body from outside and feeling as if his body was made of wood. These experiences would start within five to ten minutes and last for about one half to one hour.
Over a period of two to three months he increased the dose of ketamine five-to ten-fold to about 20 ml per day (approximately 1000 mg) divided into six or seven injections per day. During this time he only occasionally used alcohol and tranquillizers in addition.
At this time the patient sought treatment at our centre and he was admitted to the in-patient unit. He did not show any physical withdrawal symptoms from ketamine except insomnia. During his two-week admission he experienced only mild discomfort which settled with diazepam over the first few days.
DISCUSSION
This case demonstrates some well-documented features of ketamine abuse. The patient was a multiple substance user with dependence on alcohol, opioids and cannabis, although at the time of presentation he was primarily using ketamine and alcohol. Dependence on ketamine can be concluded from the rapid escalation of dose (due probably to tolerance) with significant deterioration in socio-occupational functioning. However, he experienced no physical withdrawal symptoms from ketamine. The case also demonstrated some features of the acute effects of ketamine use on perceptual and cognitive functions. These were short-lasting.
The psychotropic effects of ketamine were described during emergence from anaesthesia and are characterized by confusional state, vivid dreaming, extracorporeal experiences, illusions, euphoria and fear 3 .
The recreational use of ketamine was initially reported from the United Kingdom and United States of America in "raves" where it was used as an adulterant in methylene-dioxy-methamphetamine (MDMA) tablets and went by the name of "horse pill". Some authors 5 have reported that these ketamine users were educated, knew what they were using, how it was to be used and that they used it primarily for introspective and relaxation effects. As in our case, features were rapid induction of tolerance, a reduction in the duration of the experience with continued use, a rapid escalation of dose, no physical withdrawal symptoms and a strong tendency to use the drug repeatedly. Ketamine effects have also been described in volunteers, who express a wide range of positive and negative symptoms akin to schizophrenia 8,9 . This case also demonstrates the effects of ketamine abuse in a setting of multiple substance abuse and dependence in India. In view of the abuse liability, caution in its use is warranted. Entry of ketamine into the illicit market is a possibility and must be monitored.
